{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"thalidomide-embryopathy","columns":[{"gene":"","key":"population-05ac3b7e61e6942cc1d1","label":"Thalidomide embryopathy","mondoId":"MONDO:0018034","onsetQualifier":null,"originColumnKey":"MONDO:0018034/ORPHA:3312","originalViews":[{"key":"MONDO:0018034/ORPHA:3312","label":"Thalidomide embryopathy","scopeLabel":"ORPHA:3312","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["0fe47836448a57503740fd14e8895b0cae327b5ecc0e8599d7dd0cc06767d76c","28f01a1492bc664a0d4dcfcd4abba67acf8a75288f9cb4d85d187fa9c217c303","29eac0c68ed0b21781a4080e4c7a302287ee332a17c9a67adad57841e1e2e962","4ee1162324470660998056fb55e9e3b391ef0e41aee728f96dc4cb72402bb0df","561036ad8f1c04ca441071225c80a29fa67e2ec52a7e856c7c50a3c6354ac466","6872162d14ed69a11fd0070a2243164cd2c9a85e26cd1e6967d2fe3228441ec7","8535a5d754cd6e356abea96459b91141ac8499d528027b7734bdd322e86afd21","a09b5ff645fa3a2b31d4cb99cf66664a7cbbc95f46d55b7b0708a778d6778746","bbbdd848c1fe04f31604cbdec938e7f3ddcf90e41cf627afd146ef6ca60e6ef9","bd9ccdec856d298b86fec720677108441e4791c9707ad896278dbcb2fdb8c347","c142444ce50afd55e5d95eb09cfc6b88f55892040fe66dc340ba74bc39267f36","c9688871ab02785274019d4b5b76f64a74a3c40e593091b4f0571090130d7d29","d1615ef4a596a393ae417e12d4c8c7cab94ed0fee06354becf2114d92d5cee43","d521280392bf68a9a3a07cb22578d4184bed644ab6d88ab142f0a4e5e77d75fb","e832e226020a87fd211f189eee4314cc8df11a6e616332c2eed138b0b1a6d246","f1e78e191b8b91444a838713cdb53d044580af4fe442c30f88fc5287af16cbd0","fda555a96e7f269e9617b62e1444728c6fad15a470096e5034687783d2451b3a"],"recordQualifiers":{},"scopeLabel":"ORPHA:3312","sourceIds":["ORPHA:3312"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-05ac3b7e61e6942cc1d1"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0030680","HP:0002991","HP:0000356","HP:0009892","HP:0005613","HP:0006507","HP:0009601"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":17,"sourceGroups":{"orphanet":17}},"features":[{"hpoId":"HP:0030680","label":"Abnormal cardiovascular system morphology","primary":true},{"hpoId":"HP:0002991","label":"Abnormal fibula morphology","primary":true},{"hpoId":"HP:0000356","label":"Abnormality of the outer ear","primary":true},{"hpoId":"HP:0009892","label":"Anotia","primary":true},{"hpoId":"HP:0005613","label":"Aplasia/hypoplasia of the femur","primary":true},{"hpoId":"HP:0006507","label":"Aplasia/hypoplasia of the humerus","primary":true},{"hpoId":"HP:0009601","label":"Aplasia/Hypoplasia of the thumb","primary":true},{"hpoId":"HP:0006495","label":"Aplasia/Hypoplasia of the ulna","primary":false},{"hpoId":"HP:0002257","label":"Chronic rhinitis","primary":false},{"hpoId":"HP:0000365","label":"Hearing impairment","primary":false},{"hpoId":"HP:0000855","label":"Insulin resistance","primary":false},{"hpoId":"HP:0001177","label":"Preaxial hand polydactyly","primary":false},{"hpoId":"HP:0006433","label":"Radial ray deficiency","primary":false},{"hpoId":"HP:0004322","label":"Short stature","primary":false},{"hpoId":"HP:0001171","label":"Split hand","primary":false},{"hpoId":"HP:0001199","label":"Triphalangeal thumb","primary":false},{"hpoId":"HP:0009813","label":"Upper limb phocomelia","primary":false}],"ledeHtml":"A group of anomalies presented in infants as a result of in utero exposure (between 20-36 days after fertilization) to thalidomide, a sedative used in treatment of a range of conditions, including morning sickness, leprosy and multiple myeloma (see these terms). Thalidomine embryopathy is characterized by phocomelia, amelia, forelimb and hand plate anomalies (absence of humerus and/or forearm, femur and/or lower leg, thumb anomalies). Other anomalies include facial hemangiomas, and damages to ears (anotia, microtia), eyes (microphthalmia, anophthalmos, coloboma, strabismus), internal organs (kidney, heart, and gastrointestinal tract), genitalia, and heart. Infant mortality associated with thalidomide embryopathy is estimated to be as high as 40%. Thalidomide is contraindicated in pregnancy and pregnancy prevention is recommended in women under treatment.","mondoId":"MONDO:0018034","node":{"canonicalSlug":"thalidomide-embryopathy","comparisons":[{"documentSha256":"db079bff091f1ec0f08208f6e904843a4fec44b900c9cdd2ccdc441197de044f","key":"legacy-thalidomide-embryopathy","kind":"legacy","label":"thalidomide embryopathy","memberIds":["MONDO:0018034"],"mondoId":"MONDO:0018034","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/thalidomide-embryopathy.db079bff091f1ec0f08208f6e904843a4fec44b900c9cdd2ccdc441197de044f.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"thalidomide embryopathy","paragraphs":["A group of anomalies presented in infants as a result of in utero exposure (between 20-36 days after fertilization) to thalidomide, a sedative used in treatment of a range of conditions, including morning sickness, leprosy and multiple myeloma (see these terms). Thalidomine embryopathy is characterized by phocomelia, amelia, forelimb and hand plate anomalies (absence of humerus and/or forearm, femur and/or lower leg, thumb anomalies). Other anomalies include facial hemangiomas, and damages to ears (anotia, microtia), eyes (microphthalmia, anophthalmos, coloboma, strabismus), internal organs (kidney, heart, and gastrointestinal tract), genitalia, and heart. Infant mortality associated with thalidomide embryopathy is estimated to be as high as 40%. Thalidomide is contraindicated in pregnancy and pregnancy prevention is recommended in women under treatment."],"scope":"exact","source":"MONDO","upstream":"Orphanet:3312","url":"https://monarchinitiative.org/MONDO:0018034"},"ownColumnKeys":["population-05ac3b7e61e6942cc1d1"],"publication":"published","relationships":[{"kind":"parent","label":"syndromic disease","mondoId":"MONDO:0002254","slug":null},{"kind":"parent","label":"toxic or drug-related embryofetopathy","mondoId":"MONDO:0016677","slug":null},{"kind":"parent","label":"dysostosis","mondoId":"MONDO:0018234","slug":null},{"kind":"parent","label":"congenital limb malformation","mondoId":"MONDO:0019054","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"0fe47836448a57503740fd14e8895b0cae327b5ecc0e8599d7dd0cc06767d76c","raw":{"aspect":"P","body_system":"growth","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0004322","is_excluded":false,"label":"Short stature","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"28f01a1492bc664a0d4dcfcd4abba67acf8a75288f9cb4d85d187fa9c217c303","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0005613","is_excluded":false,"label":"Aplasia/hypoplasia of the femur","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"29eac0c68ed0b21781a4080e4c7a302287ee332a17c9a67adad57841e1e2e962","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0009813","is_excluded":false,"label":"Upper limb phocomelia","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4ee1162324470660998056fb55e9e3b391ef0e41aee728f96dc4cb72402bb0df","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0009601","is_excluded":false,"label":"Aplasia/Hypoplasia of the thumb","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"561036ad8f1c04ca441071225c80a29fa67e2ec52a7e856c7c50a3c6354ac466","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001177","is_excluded":false,"label":"Preaxial hand polydactyly","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"6872162d14ed69a11fd0070a2243164cd2c9a85e26cd1e6967d2fe3228441ec7","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0009892","is_excluded":false,"label":"Anotia","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8535a5d754cd6e356abea96459b91141ac8499d528027b7734bdd322e86afd21","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0006507","is_excluded":false,"label":"Aplasia/hypoplasia of the humerus","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"a09b5ff645fa3a2b31d4cb99cf66664a7cbbc95f46d55b7b0708a778d6778746","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0006433","is_excluded":false,"label":"Radial ray deficiency","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bbbdd848c1fe04f31604cbdec938e7f3ddcf90e41cf627afd146ef6ca60e6ef9","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0006495","is_excluded":false,"label":"Aplasia/Hypoplasia of the ulna","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bd9ccdec856d298b86fec720677108441e4791c9707ad896278dbcb2fdb8c347","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002991","is_excluded":false,"label":"Abnormal fibula morphology","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c142444ce50afd55e5d95eb09cfc6b88f55892040fe66dc340ba74bc39267f36","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002257","is_excluded":false,"label":"Chronic rhinitis","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c9688871ab02785274019d4b5b76f64a74a3c40e593091b4f0571090130d7d29","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000356","is_excluded":false,"label":"Abnormality of the outer ear","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d1615ef4a596a393ae417e12d4c8c7cab94ed0fee06354becf2114d92d5cee43","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000855","is_excluded":false,"label":"Insulin resistance","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d521280392bf68a9a3a07cb22578d4184bed644ab6d88ab142f0a4e5e77d75fb","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001199","is_excluded":false,"label":"Triphalangeal thumb","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e832e226020a87fd211f189eee4314cc8df11a6e616332c2eed138b0b1a6d246","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0030680","is_excluded":false,"label":"Abnormal cardiovascular system morphology","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f1e78e191b8b91444a838713cdb53d044580af4fe442c30f88fc5287af16cbd0","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000365","is_excluded":false,"label":"Hearing impairment","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"fda555a96e7f269e9617b62e1444728c6fad15a470096e5034687783d2451b3a","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3312","disease_name":"Thalidomide embryopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001171","is_excluded":false,"label":"Split hand","onset_id":null,"reference":"ORPHA:3312","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0018034\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:3312</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A group of anomalies presented in infants as a result of in utero exposure (between 20-36 days after fertilization) to thalidomide, a sedative used in treatment of a range of conditions, including morning sickness, leprosy and multiple myeloma (see these terms). Thalidomine embryopathy is characterized by phocomelia, amelia, forelimb and hand plate anomalies (absence of humerus and/or forearm, femur and/or lower leg, thumb anomalies). Other anomalies include facial hemangiomas, and damages to ears (anotia, microtia), eyes (microphthalmia, anophthalmos, coloboma, strabismus), internal organs (kidney, heart, and gastrointestinal tract), genitalia, and heart. Infant mortality associated with thalidomide embryopathy is estimated to be as high as 40%. Thalidomide is contraindicated in pregnancy and pregnancy prevention is recommended in women under treatment.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0018034\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"thalidomide-embryopathy","sourceDocuments":[{"name":"MONDO: thalidomide embryopathy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0018034"}],"sourceNote":"","synonyms":["fetal thalidomide syndrome","foetal thalidomide syndrome","thalidomide embryopathy syndrome","thalidomide-induced birth defect"],"takeawayHtml":"","title":"thalidomide embryopathy"},"schemaVersion":1}
